INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 152 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.31 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,658,896 | -79.3% | 143,414 | -87.7% | 0.00% | -75.0% |
| Q2 2023 | $12,845,095 | +140.6% | 1,161,401 | +192.2% | 0.01% | +100.0% |
| Q1 2023 | $5,337,955 | +14.6% | 397,465 | +5.5% | 0.00% | 0.0% |
| Q4 2022 | $4,659,123 | +5.4% | 376,647 | +18.8% | 0.00% | +33.3% |
| Q3 2022 | $4,421,000 | +16.6% | 316,927 | +15.5% | 0.00% | 0.0% |
| Q2 2022 | $3,791,000 | +53.4% | 274,504 | +80.8% | 0.00% | +50.0% |
| Q1 2022 | $2,471,000 | -54.7% | 151,858 | -54.6% | 0.00% | -33.3% |
| Q4 2021 | $5,452,000 | +67.5% | 334,691 | +52.7% | 0.00% | +50.0% |
| Q3 2021 | $3,254,000 | -36.3% | 219,153 | -14.4% | 0.00% | -33.3% |
| Q2 2021 | $5,112,000 | +13.0% | 255,987 | +30.7% | 0.00% | 0.0% |
| Q1 2021 | $4,522,000 | +130.8% | 195,933 | +147.0% | 0.00% | +200.0% |
| Q4 2020 | $1,959,000 | -53.1% | 79,323 | -21.3% | 0.00% | -66.7% |
| Q3 2020 | $4,178,000 | -33.3% | 100,751 | -22.9% | 0.00% | -40.0% |
| Q2 2020 | $6,260,000 | +10.4% | 130,665 | +45.0% | 0.01% | 0.0% |
| Q1 2020 | $5,672,000 | -75.9% | 90,093 | -52.5% | 0.01% | -68.8% |
| Q4 2019 | $23,517,000 | +78.0% | 189,772 | -4.7% | 0.02% | +45.5% |
| Q3 2019 | $13,212,000 | -2.9% | 199,099 | +16.4% | 0.01% | 0.0% |
| Q2 2019 | $13,611,000 | -25.3% | 171,059 | +5.0% | 0.01% | -35.3% |
| Q1 2019 | $18,229,000 | +31.3% | 162,958 | +18.3% | 0.02% | +21.4% |
| Q4 2018 | $13,885,000 | +26.7% | 137,762 | +58.8% | 0.01% | +40.0% |
| Q3 2018 | $10,961,000 | +89.4% | 86,739 | +25.8% | 0.01% | +66.7% |
| Q2 2018 | $5,787,000 | +122.1% | 68,972 | +62.8% | 0.01% | +200.0% |
| Q1 2018 | $2,606,000 | -19.4% | 42,357 | -23.5% | 0.00% | 0.0% |
| Q4 2017 | $3,233,000 | -34.6% | 55,350 | -35.0% | 0.00% | -60.0% |
| Q3 2017 | $4,946,000 | -60.6% | 85,207 | -17.9% | 0.01% | -54.5% |
| Q2 2017 | $12,568,000 | +215.5% | 103,810 | +194.7% | 0.01% | +266.7% |
| Q1 2017 | $3,984,000 | -84.9% | 35,228 | -85.5% | 0.00% | -87.5% |
| Q4 2016 | $26,319,000 | +51.3% | 242,247 | +129.2% | 0.02% | +50.0% |
| Q3 2016 | $17,395,000 | +25.6% | 105,686 | +8.8% | 0.02% | +14.3% |
| Q2 2016 | $13,855,000 | +25.1% | 97,105 | +12.7% | 0.01% | +7.7% |
| Q1 2016 | $11,074,000 | -4.0% | 86,195 | +11.6% | 0.01% | +8.3% |
| Q4 2015 | $11,536,000 | +8.6% | 77,242 | +20.6% | 0.01% | +20.0% |
| Q3 2015 | $10,623,000 | -10.0% | 64,052 | +31.0% | 0.01% | 0.0% |
| Q2 2015 | $11,803,000 | -45.8% | 48,898 | -36.7% | 0.01% | -50.0% |
| Q1 2015 | $21,777,000 | +354.1% | 77,213 | +151.1% | 0.02% | +400.0% |
| Q4 2014 | $4,796,000 | +0.5% | 30,745 | +52.5% | 0.00% | 0.0% |
| Q3 2014 | $4,772,000 | +111.5% | 20,158 | +111.4% | 0.00% | +100.0% |
| Q2 2014 | $2,256,000 | +61.8% | 9,535 | +125.6% | 0.00% | +100.0% |
| Q1 2014 | $1,394,000 | +799.4% | 4,227 | +87.2% | 0.00% | – |
| Q4 2013 | $155,000 | +15400.0% | 2,258 | +24988.9% | 0.00% | – |
| Q3 2013 | $1,000 | 0.0% | 9 | -67.9% | 0.00% | – |
| Q2 2013 | $1,000 | – | 28 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |